These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 3785144

  • 1. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
    Kontoghiorghes GJ.
    Mol Pharmacol; 1986 Dec; 30(6):670-3. PubMed ID: 3785144
    [Abstract] [Full Text] [Related]

  • 2. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
    Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L.
    Am J Hematol; 1993 Apr; 42(4):340-9. PubMed ID: 8493983
    [Abstract] [Full Text] [Related]

  • 3. Orally active alpha-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations.
    Kontoghiorghes GJ.
    Acta Haematol; 1987 Apr; 78(2-3):212-6. PubMed ID: 3120474
    [Abstract] [Full Text] [Related]

  • 4. Dose response studies using desferrioxamine and orally active chelators in a mouse model.
    Kontoghiorghes GJ.
    Scand J Haematol; 1986 Jul; 37(1):63-70. PubMed ID: 3764334
    [Abstract] [Full Text] [Related]

  • 5. Chelators affecting iron absorption in mice.
    Kontoghiorghes GJ.
    Arzneimittelforschung; 1990 Dec; 40(12):1332-5. PubMed ID: 2095129
    [Abstract] [Full Text] [Related]

  • 6. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
    Brock JH, Licéaga J, Arthur HM, Kontoghiorghes GJ.
    Am J Hematol; 1990 May; 34(1):21-5. PubMed ID: 2327400
    [Abstract] [Full Text] [Related]

  • 7. In vivo evaluation of hydroxypyridone iron chelators in a mouse model.
    Gyparaki M, Porter JB, Hirani S, Streater M, Hider RC, Huehns ER.
    Acta Haematol; 1987 May; 78(2-3):217-21. PubMed ID: 3120475
    [Abstract] [Full Text] [Related]

  • 8. New orally active alpha-ketohydroxy pyridine chelators for the treatment of iron overload.
    Kontoghiorghes GJ.
    Birth Defects Orig Artic Ser; 1988 May; 23(5B):97-103. PubMed ID: 3390580
    [No Abstract] [Full Text] [Related]

  • 9. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
    Kontoghiorghes GJ, Sheppard L, Hoffbrand AV, Charalambous J, Tikerpae J, Pippard MJ.
    J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
    [Abstract] [Full Text] [Related]

  • 10. New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones.
    Kontoghiorghes GJ, Sheppard L, Chambers S.
    Arzneimittelforschung; 1987 Oct; 37(10):1099-102. PubMed ID: 3435580
    [Abstract] [Full Text] [Related]

  • 11. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
    Rai BL, Dekhordi LS, Khodr H, Jin Y, Liu Z, Hider RC.
    J Med Chem; 1998 Aug 27; 41(18):3347-59. PubMed ID: 9719587
    [Abstract] [Full Text] [Related]

  • 12. Iron mobilisation from lactoferrin by chelators at physiological pH.
    Kontoghiorghes GJ.
    Biochim Biophys Acta; 1986 Jun 19; 882(2):267-70. PubMed ID: 3708002
    [Abstract] [Full Text] [Related]

  • 13. Site specificity of iron removal from transferrin by alpha-ketohydroxypyridine chelators.
    Kontoghiorghes GJ, Evans RW.
    FEBS Lett; 1985 Sep 09; 189(1):141-4. PubMed ID: 4029396
    [Abstract] [Full Text] [Related]

  • 14. The effect of 2,4-dihydroxypyridine-N-oxide, a new orally active iron chelator, on iron excretion in mice.
    Kontoghiorghes GJ.
    Clin Chim Acta; 1987 Mar 16; 163(2):137-41. PubMed ID: 3568416
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
    Kontoghiorghes GJ.
    Toxicol Lett; 1995 Oct 16; 80(1-3):1-18. PubMed ID: 7482575
    [Abstract] [Full Text] [Related]

  • 16. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
    Hoyes KP, Jones HM, Abeysinghe RD, Hider RC, Porter JB.
    Exp Hematol; 1993 Jan 16; 21(1):86-92. PubMed ID: 8417963
    [Abstract] [Full Text] [Related]

  • 17. Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits.
    Kontoghiorghes GJ, Hoffbrand AV.
    Br J Haematol; 1986 Apr 16; 62(4):607-13. PubMed ID: 3964556
    [Abstract] [Full Text] [Related]

  • 18. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
    Morel I, Cillard J, Lescoat G, Sergent O, Pasdeloup N, Ocaktan AZ, Abdallah MA, Brissot P, Cillard P.
    Free Radic Biol Med; 1992 Nov 16; 13(5):499-508. PubMed ID: 1334028
    [Abstract] [Full Text] [Related]

  • 19. Alternative treatment paradigm for thalassemia using iron chelators.
    Szuber N, Buss JL, Soe-Lin S, Felfly H, Trudel M, Ponka P.
    Exp Hematol; 2008 Jul 16; 36(7):773-85. PubMed ID: 18456387
    [Abstract] [Full Text] [Related]

  • 20. Topical applications of iron chelators in photosensitization.
    Juzeniene A, Juzenas P, Iani V, Moan J.
    Photochem Photobiol Sci; 2007 Dec 16; 6(12):1268-74. PubMed ID: 18046481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.